Joseph C Mello Net Worth

The estimated Net Worth of Joseph C Mello is at least $9.31 Million dollars as of 16 September 2008. Joseph Mello owns over 37,500 units of DaVita Inc stock worth over $2,646,780 and over the last 21 years Joseph sold DVA stock worth over $6,663,014.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Joseph Mello DVA stock SEC Form 4 insiders trading

Joseph has made over 38 trades of the DaVita Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Joseph exercised 37,500 units of DVA stock worth $1,771,125 on 16 September 2008.

The largest trade Joseph's ever made was exercising 101,250 units of DaVita Inc stock on 1 July 2004 worth over $426,263. On average, Joseph trades about 27,316 units every 39 days since 2003. As of 16 September 2008 Joseph still owns at least 17,188 units of DaVita Inc stock.

You can see the complete history of Joseph Mello stock trades at the bottom of the page.

What's Joseph Mello's mailing address?

Joseph's mailing address filed with the SEC is 21250 HAWTHORNE BLVD., SUITE #800, TORRANCE, CA, 90503.

Insiders trading at DaVita Inc

Over the last 22 years, insiders at DaVita Inc have traded over $539,813,199 worth of DaVita Inc stock and bought 20,841,023 units worth $1,590,012,094 . The most active insiders traders include Hathaway Incbuffett Warren ..., R. Ted Weschler,, and Kent J Thiry. On average, DaVita Inc executives and independent directors trade stock every 12 days with the average trade being worth of $12,626,872. The most recent stock trade was executed by Kathleen Alyce Waters on 28 August 2024, trading 26,333 units of DVA stock currently worth $1,999,991.

What does DaVita Inc do?

about davita kidney care davita kidney care is a division of davita healthcare partners inc., a fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the united states and abroad. a leading provider of dialysis services in the united states, davita kidney care treats patients with chronic kidney failure and end stage renal disease. davita kidney care strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. as of march 31, 2015, davita kidney care operated or provided administrative services at 2,197 outpatient dialysis centers located in the united states serving approximately 174,000 patients. the company also operated 93 outpatient dialysis centers located in 10 countries outside the united states. davita kidney care supports numerous programs dedicated to creating positive,

Complete history of Joseph Mello stock trades at DaVita Inc

DaVita Inc executives and stock owners

DaVita Inc executives and other stock owners filed with the SEC include:

• Javier Rodriguez,
  Chief Executive Officer, Director
• Joel Ackerman,
  Chief Financial Officer, Treasurer
• Charles Berg,
  Director
• Kathleen Waters,
  Chief Legal Officer
• Javier J. Rodriguez,
  CEO & Exec. Director
• LeAnne Zumwalt,
  Group Vice President, Government Affairs
• Michael David Staffieri,
  Chief Operating Officer of Kidney Care
• Joel Ackerman,
  CFO & Treasurer
• Kathleen Alyce Waters,
  Chief Legal and Public Affairs Officer
• James O. Hearty,
  Chief Compliance Officer
• Barbara Desoer,
  Independent Director
• Pascal Desroches,
  Independent Director
• Pamela Arway,
  Independent Chairman of the Board
• John Nehra,
  Independent Director
• Paul Diaz,
  Independent Director
• Phyllis Yale,
  Independent Director
• Jim Gustafson,
  Vice President - Investor Relations
• Paula Price,
  Independent Director
• Shawn Guertin,
  Director
• Kenny Gardner,
  Chief People Officer - DaVita Kidney Care
• James Hearty,
  Chief Compliance Officer
• John Winstel,
  Chief Accounting Officer
• Kenneth Gardner Smith,
  Chief People Officer
• Kenny Gardner,
  Chief People Officer
• Atul Mathur,
  Exec. VP of Global Operations
• Bill Myers,
  VP of Marketing & Communications
• John D. Winstel,
  Chief Accounting Officer
• Jeanine Marie Jiganti,
  Chief Compliance Officer
• Peter T Grauer,
  Director
• James K Hilger,
  Vice President and Controller
• William L Roper,
  Director
• Carol Anthony Davidson,
  Director
• Roger Valine,
  Director
• Joseph C Mello,
  Chief Operations Officer
• Allen Nissenson,
  Chief Medical Officer
• Dennis W Pullin,
  Director
• R. Ted Weschler,,
  
• Hathaway Incbuffett Warren ...,
  
• Robert J Margolis,
  Co-Chairman of the Board
• Laura Mildenberger,
  SVP & Chief People Officer
• Kim M Rivera,
  VP, Gen. Counsel & Secretary
• Dennis Kogod,
  President - West
• Garry E Menzel,
  Senior Vice President, Finance
• David T Shapiro,
  Chief Compliance Officer
• Charles J Mcallister,
  Chief Medical Officer
• Steven J Udicious,
  V.P., Sec. and Gen. Counsel
• Joseph Schohl,
  VP, Secretary & Gen. Counsel
• Willard Woodson Jr Brittain,
  Director
• Nancy Ann Deparle,
  Director
• Mary Kowenhoven,
  Vice President - Strategy
• Thomas O Usilton,
  Group Vice President
• Patricia Jones,
  Chief People Officer
• C Raymond Jr Larkin,
  Director
• Christopher J Riopelle,
  Chief Compliance Officer
• Thomas L Kelly,
  Executive Vice President
• Luis Borgen,
  Chief Financial Officer
• Georgina Randolph,
  Senior Vice President
• Richard B Fontaine,
  Director
• Mark G Harrison,
  Chief Financial Officer
• Richard K Whitney,
  Chief Financial Officer
• Richard C Vaughan,
  Director
• Gary Beil,
  Vice President and Controller
• Patrick A Broderick,
  VP, Secretary & Gen. Counsel
• Lori Richardson Pelliccioni,
  Cheif Compliance Officer
• Michele J Hooper,
  Director
• Michael David Staffieri,
  Chief Operating Officer, DKC
• Kent J Thiry,
  Executive Chairman
• Gregory J. Moore,
  Director
• Jason M. Hollar,
  Director
• Adam H Schechter,
  Director
• Christopher Michael Berry,
  Chief Accounting Officer
• Wendy Lee Schoppert,
  Director